Who can use Jaypirca(Pirtobrutinib)?

The specific medical conditions the drug is approved to treat.

Approved Uses

JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least two prior systemic therapies, including a BTK inhibitor. It is also indicated for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including both a BTK inhibitor and a BCL-2 inhibitor. These approvals were granted under the FDA's accelerated approval pathway based on observed response rates.

Related Columns

Pirtobrutinib(Jaypirca)

Treatment of relapsed or refractory mantle cell lymphoma (MCL) and chronic...

WeChat Scan
Free Inquiry

What Are the Indications for Pirtobrutinib?

Pirtobrutinib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a non-covalent inhibitor of Bruton's Tyrosine Kinase (BTK), it demonstrates unique advan...

Pirtobrutinib instructions

Pirtobrutinib is an innovative kinase inhibitor that shows good potential in the treatment of specific blood diseases. This article will comprehensively analyze Pirtobrutinib from three aspe...

Indications for Pirtobrutinib

Pirtobrutinib is a drug used to treat certain types of lymphoma and leukemia. It is mainly used for patients who have not responded well to other treatments or have relapsed. This article will ex...